Cyclacel Pharmaceuticals - CYCC Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYCC shares.
View CYCC analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12 month target prices for Cyclacel Pharmaceuticals' stock. Their CYCC share price forecasts range from $17.00 to $17.00. On average, they anticipate the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 1,249.2% from the stock's current price.
View analysts price targets for CYCC or view top-rated stocks among Wall Street analysts.

Cyclacel Pharmaceuticals' stock was trading at $3.89 at the beginning of 2022. Since then, CYCC shares have decreased by 67.6% and is now trading at $1.26.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our CYCC earnings forecast.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) announced its quarterly earnings results on Wednesday, August, 10th. The biotechnology company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.67) by $0.21. During the same quarter in the previous year, the business earned ($0.56) earnings per share.

Cyclacel Pharmaceuticals shares reverse split before market open on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 14th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

Cyclacel Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sio Capital Management LLC (4.55%), Millennium Management LLC (1.04%), Renaissance Technologies LLC (0.63%) and Virtu Financial LLC (0.31%). Insiders that own company stock include Sam L Barker and Spiro George Rombotis.
View institutional ownership trends.

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CYCC stock can currently be purchased for approximately $1.26.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) has a market capitalization of $15.80 million. The biotechnology company earns $-18,890,000.00 in net income (profit) each year or ($1.96) on an earnings per share basis.

The company employs 2,018 workers across the globe.

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The official website for the company is www.cyclacel.com. The biotechnology company can be reached via phone at (908) 517-7330, via email at ir@cyclacel.com, or via fax at 866-271-3466.